Microsoft Recommends Philips SpeechMike Premium Touch as the Successor to Nuance PowerMic

7.5.2025 14:00:00 CEST | Business Wire | Press Release

Speech Processing Solutions, global leader in professional dictation solutions under the Philips brand, today announced that the Philips SpeechMike Premium Touch has been officially recognized by Microsoft as the recommended successor to the soon-to-be-retired Nuance PowerMic series.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507643740/en/

The Philips SpeechMike Premium Touch.

As the only microphone recommended by Microsoft for PowerMic replacement, the Philips SpeechMike Premium Touch delivers seamless, plug-and-play compatibility with many Nuance speech recognition solutions, including Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe offering medical, legal and business professionals a superior alternative for uninterrupted documentation workflows.

With an intuitive button layout mirroring the PowerMic, the Philips SpeechMike Premium Touch offers users a familiar, yet enhanced dictation experience to enable effortless transitions. Already in use by millions of medical, legal and business professionals worldwide, the Philips SpeechMike Premium Touch offers:

Compatibility with Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe, as well as other legacy software such as Dragon NaturallySpeaking, Dragon Medical Practice Edition, and Winscribe
Pre-configured Dragon function keys for convenient speech recognition control
Studio-quality microphone with noise reduction for unprecedented accuracy in speech recognition
Ergonomic design and hygienic housing, ideal for long-shift use and clinical work environments
Advanced touch sensor navigation replaces the need to switch to a mouse

“With the PowerMic now being retired in the coming weeks, organizations must move quickly to maintain continuity in documentation,” said Dr. Thomas Brauner, CEO at Speech Processing Solutions. “The Philips SpeechMike Premium Touch is delivering both familiarity and unprecedented quality in speech recognition accuracy. I am delighted to be able to offer the Philips SpeechMike – the leading and most widely used dictation microphone in the world – to all existing PowerMic users.”

The Philips SpeechMike Premium Touch is available now through professional distribution channels.

Speech Processing Solutions (SPS):

Speech Processing Solutions (SPS) is the global leader in AI-powered dictation and transcription solutions. Active in over 50 countries with more than 4 million users and a network of 1,000+ partners, SPS develops award-winning speech-to-text technologies and devices under the Philips brand. Headquartered in Vienna, Austria, SPS is globally active with offices in Australia, Canada, Belgium, France, Germany, the UK, and the US.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250507643740/en/

Contacts

Press Contact:
Speech Processing Solutions
Alice Elt
Content & PR Manager
Email: alice.elt@speech.com
www.philips.com/dictation -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.philips.com
%2Fdictation&esheet=54250519&newsitemid=20250507643740&lan=en-US&anchor=www.phil
ips.com%2Fdictation&index=1&md5=4ebfbd075bc4030d7af0e4df6074c7f7 |
www.speechlive.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.speechlive.
com%2F&esheet=54250519&newsitemid=20250507643740&lan=en-US&anchor=www.speechlive
.com&index=2&md5=487585fc307509b39270f33138c5b480

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom